The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
Lancet Gastroenterol Hepatol. 2022 May;7(5):426-445. doi: 10.1016/S2468-1253(21)00471-4. Epub 2022 Mar 15.
Despite the goal set by WHO to eliminate hepatitis C virus (HCV) as a public health threat, uptake of HCV testing and treatment remains low. To achieve this target, evidence-based interventions are needed to address the barriers to care for people with, or at risk of, HCV infection. We aimed to assess the efficacy of interventions to improve HCV antibody testing, HCV RNA testing, linkage to HCV care, and treatment initiation.
In this systematic review and meta-analysis, we searched MEDLINE (PubMed), Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, and PsycINFO without language restrictions for reports published between database inception and July 21, 2020, assessing the following primary outcomes: HCV antibody testing; HCV RNA testing; linkage to HCV care; and direct-acting antiviral treatment initiation. We also searched key conference abstracts. We included randomised and non-randomised studies assessing non-pharmaceutical interventions that included a comparator or control group. Studies were excluded if they enrolled only paediatric populations (aged <18 years) or if they conducted the intervention in a different health-care setting to that of the control or comparator. Authors were contacted to clarify study details and to obtain additional population-level data. Data were extracted from the records identified into a pre-piloted and standardised data extraction form and a random-effects meta-analysis was used to pool the effects of the interventions on study outcomes. This study is registered in PROSPERO, CRD42020178035.
Of 15 342 unique records identified, 142 were included, which reported on 148 unique studies (47 randomised controlled trials and 101 non-randomised studies). Medical chart reminders, provider education, and point-of-care antibody testing significantly improved at least three study outcomes compared with a comparator or control. Interventions that simplified HCV testing, including dried blood spot testing, point-of-care antibody testing, reflex RNA testing, and opt-out screening, significantly improved testing outcomes compared with a comparator or control. Enhanced patient and provider support through patient education, provider care coordination, and provider education also significantly improved testing outcomes compared with a comparator or control. Integrated care and patient navigation or care coordination significantly improved linkage to care and the uptake of direct-acting antiviral treatment compared with a comparator or control.
Several interventions to improve HCV care that address several key barriers to HCV care were identified. New models of HCV care must be designed and implemented to address the barriers faced by the population of interest. Further high-quality research, including rigorously designed randomised studies, is still needed in key populations.
None.
尽管世界卫生组织(WHO)设定了消除丙型肝炎病毒(HCV)这一公共卫生威胁的目标,但 HCV 检测和治疗的普及率仍然很低。为了实现这一目标,需要采取循证干预措施来解决 HCV 感染者或有感染风险者的护理障碍。我们旨在评估提高 HCV 抗体检测、HCV RNA 检测、与 HCV 护理的衔接以及治疗启动率的干预措施的疗效。
在本系统评价和荟萃分析中,我们检索了 MEDLINE(PubMed)、Scopus、Web of Science、Cochrane 对照试验中心注册库和 PsycINFO,检索时间截至 2020 年 7 月 21 日,报告了以下主要结局:HCV 抗体检测;HCV RNA 检测;与 HCV 护理的衔接;以及直接作用抗病毒治疗的启动。我们还检索了主要会议摘要。我们纳入了评估包括对照或对照组的非药物干预的随机和非随机研究。如果研究仅纳入儿科人群(年龄<18 岁),或在与对照组或对照相比不同的医疗保健环境中进行干预,则将研究排除在外。我们联系了作者以澄清研究细节并获得额外的人群水平数据。从确定的记录中提取数据到预编程和标准化的数据提取表中,并使用随机效应荟萃分析来汇总干预对研究结果的影响。本研究已在 PROSPERO 注册,CRD42020178035。
在 15342 条唯一记录中,有 142 条被纳入,其中报告了 148 项独特的研究(47 项随机对照试验和 101 项非随机对照试验)。与对照组相比,医疗图表提醒、提供者教育和即时护理点抗体检测显著改善了至少三个研究结局。与对照组相比,简化 HCV 检测的干预措施,包括干血斑检测、即时护理点抗体检测、反射 RNA 检测和选择性筛查,显著改善了检测结果。通过患者教育、提供者护理协调和提供者教育增强患者和提供者的支持,也显著改善了与对照组相比的检测结果。综合护理和患者导航或护理协调显著改善了与护理的衔接以及直接作用抗病毒治疗的采用率,与对照组相比。
确定了几种改善 HCV 护理的干预措施,这些措施解决了 HCV 护理的几个关键障碍。必须设计和实施新的 HCV 护理模式,以解决目标人群所面临的障碍。在关键人群中,仍需要进一步开展高质量的研究,包括精心设计的随机研究。
无。